Irinto (Irinotecan Hydrochloride Trihydrate)

• Irinto (irinotecan) is used in the treatment of colorectal cancer, targeting tumor growth and spread.
• Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens.
• Advanced colorectal cancer: reduces tumor burden and may extend progression‑free survival.
• Colorectal cancer refractory to standard therapy: provides an additional therapeutic option.

• Irinotecan is converted intracellularly to its active metabolite SN‑38, which binds to and stabilizes the DNA‑topoisomerase I complex. This prevents relegation of single‑strand DNA breaks, leading to accumulation of DNA damage, inhibition of DNA replication, and ultimately cancer cell death.

Common Side Effects

• Diarrhea: may be severe and require supportive care.
• Nausea and vomiting: often managed with anti‑emetics.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: hair loss during treatment cycles.
• Fatigue: general tiredness and weakness.
• Elevated liver enzymes: mild hepatic irritation.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count, a medical emergency.
• Severe colitis or life‑threatening diarrhea.
• Hepatic toxicity: significant liver function impairment.
• Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Cardiac toxicity: rare arrhythmias or myocardial injury.
• Secondary malignancies: very rare long‑term risk.

• Patients receiving Irinto require careful monitoring and individualized care.
• Dose adjustment: required for patients with hepatic impairment.
• Monitoring: regular complete blood counts to detect neutropenia.
• Hydration: ensure adequate fluids to mitigate diarrhea.
• Drug interactions: avoid concurrent strong CYP3A4 inhibitors.
• Pregnancy: contraindicated or use only if benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with several medicines, necessitating vigilance.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase toxicity.
• Live vaccines: heightened infection risk due to immunosuppression.
• Concurrent high‑dose radiation therapy: amplified severe diarrhea.
• Other topoisomerase I inhibitors: additive toxicity.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin): may reduce efficacy.
• Anticoagulants (e.g., warfarin): monitor INR for bleeding.
• Nephrotoxic agents (e.g., cisplatin): watch renal function.
• Antidiarrheal agents (e.g., loperamide) at high doses: risk of ileus.
• Herbal supplements (e.g., St. John’s wort): possible reduced exposure.